Trastuzumab-DM1: Phase II data

The open-label, international Phase II TDM4450g trial in 137 treatment-naïve patients showed that 3.6 mg/kg IV T-DM1 every 3 weeks produced an ORR of 48%, including 3 complete responses (CR) and 29

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE